Claims for Patent: 10,016,440

✉ Email this page to a colleague

Summary for Patent: 10,016,440

Title:	Methods of enhancing antibody-dependent cellular cytotoxicity
Abstract:	The application relates to method of increasing antibody-dependent cellular cytotoxicity in a subject receiving therapeutic monoclonal antibody treatment. In some embodiments, methods are provided for administering to subject to a subject in need thereof a therapeutic antibody in conjunction with an ADCC enhancer molecule.
Inventor(s):	Hershberg; Robert (Seattle, WA)
Assignee:	VentiRx Pharmaceuticals, Inc. (Seattle, WA)
Application Number:	13/092,088
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 10,016,440
Patent Claims:	1. A method of increasing antibody-dependent cellular cytotoxicity (ADCC) in a subject receiving therapeutic monoclonal antibody treatment comprising administering to the subject a therapeutic monoclonal antibody and an ADCC enhancer molecule in an amount sufficient to increase ADCC, wherein the ADCC enhancer molecule is {2-amino-8-[4-(pyrrolidinylcarbonyl)phenyl]-(3H-benzo[f]azepin-4-yl)}-N,N- -dipropylcarboxamide. 2. The method of claim 1, wherein the therapeutic monoclonal antibody is a therapeutic anti-CD20 monoclonal antibody, a therapeutic anti-Her2 monoclonal antibody, or a therapeutic anti-EGFR monoclonal antibody. 3. The method of claim 1, wherein the therapeutic monoclonal antibody is rituximab, trastuzumab, cetuximab, or panitumumab. 4. The method of claim 1, further comprising administering to the subject a therapeutically effective amount of one or more chemotherapeutic agents. 5. The method of claim 1, wherein the subject has an Fc.gamma.R polymorphism or a KRAS mutation. 6. The method of claim 1, wherein the subject has previously been identified as being unresponsive to therapeutic antibody treatment. 7. The method of claim 1, wherein the subject has impaired ADCC function. 8. The method of claim 1, wherein the ADCC enhancer molecule is administered prior to, concurrently with, subsequent to the administration of the therapeutic antibody.

Details for Patent 10,016,440

Glossary

Subscribe to access the full database, or Subscribe
Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Genentech, Inc.	RITUXAN	rituximab	Injection	103705	November 26, 1997	⤷ Subscribe	2030-04-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	September 25, 1998	⤷ Subscribe	2030-04-21
Genentech, Inc.	HERCEPTIN	trastuzumab	For Injection	103792	February 10, 2017	⤷ Subscribe	2030-04-21
>Applicant	>Tradename	>Biologic Ingredient	>Dosage Form	>BLA	>Approval Date	>Patent No.	>Expiredate

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.